Company profile: Quoin Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of pharmaceutical products under development addressing major unmet medical needs, including QRX003, a topical lotion in clinical evaluation for Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma; QRX008 for Scleroderma; QRX007 for Netherton Syndrome; and QRX004 for Epidermolysis Bullosa.
Products and services
- QRX003: Clinical-stage topical lotion under evaluation to treat Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma, featuring a skin-directed topical formulation
- QRX004: Candidate-stage therapeutic aimed at treating Epidermolysis Bullosa, architected to address this condition with a focused treatment approach
- QRX007: In-development therapeutic candidate for Netherton Syndrome, engineered to target this condition with a dedicated treatment under active development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Quoin Pharmaceuticals
Achieve Life Sciences
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products, manufacturing and developing cytisinicline, a plant-based alkaloid for nicotine addiction, including smoking and e-cigarette cessation, that interacts with nicotine receptors to reduce withdrawal symptoms and the reward associated with nicotine products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achieve Life Sciences company profile →
Neurimmune
HQ: Switzerland
Website
- Description: Provider of immunotherapeutics using a Reverse Translational Medicine (RTM) platform to generate recombinant human-derived monoclonal antibodies. Pipeline includes NI101SQ (subcutaneous aducanumab) for Alzheimer’s, AP-101 for ALS, ALXN2220 for ATTR-CM, NI203 for type-2 diabetes, and human anti-SARS-CoV-2 antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurimmune company profile →
Latigo Bio
HQ: United States
Website
- Description: Provider of clinical-stage, non-opioid therapies for chronic pain, including LTGO-33, a selective NaV1.8 inhibitor, and a Nav1.8 pain program. Leverages ion channel expertise, human tissue and genetic data, a proprietary discovery engine, and multiparameter optimization to identify, validate, and optimize small-molecule candidates targeting pain-related channels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Latigo Bio company profile →
Seaport Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical solutions, including the Glyph platform, a proprietary lymphatic-targeting technology enabling and enhancing oral drug administration by bypassing first-pass metabolism and reducing hepatotoxicity, and SPT-300, an oral prodrug of allopregnanolone for treating mood and anxiety disorders, including anxious depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seaport Therapeutics company profile →
Statera Spine
HQ: United States
Website
- Description: Provider of software-enabled spine imaging analytics solutions for chronic and acute spine issues, offering diagnostic and decision-making tools including Profile-ESP for standardized spinal motion and alignment data reports, and VMA, a fluoroscopy imaging system assessing spinal instability and sagittal alignment with measurements for surgical decisions and insurance disputes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Statera Spine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Quoin Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Quoin Pharmaceuticals
2.2 - Growth funds investing in similar companies to Quoin Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Quoin Pharmaceuticals
4.2 - Public trading comparable groups for Quoin Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →